Juvmo (tavapadon)
AbbVie (ABBV)
ApprovedSep 25, 2026
Marketer take
A new Parkinson's option in a crowded, largely generic market built on levodopa and dopamine agonists, so movement-disorder specialists and neurologists will need clear positioning on where it fits in therapy.
- Sponsor company
- AbbVie (ABBV)
- Indication
- To treat Parkinson’s disease in adults
- Therapeutic area
- Neurology
- Event
- FDA approval
- Date
- Sep 25, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?